Skip to content

Social Relationships and Accelerated Aging in Hematopoietic Cell Transplant Survivors

Accelerated Biological and Phenotypic Aging in Hematopoietic Cell Transplant Survivors: Social Support as a Protective Factor

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT04892823
Enrollment
110
Registered
2021-05-19
Start date
2021-05-18
Completion date
2027-07-16
Last updated
2026-08-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hematopoietic and Lymphoid Cell Neoplasm

Brief summary

This project aims to elucidate the important protective elements of social relationships and identify concrete, modifiable behavioral factors that contribute to biological and phenotypic aging in hematopoietic cell transplantation (HCT) survivors and can be used to develop biologically informed interventions to improve quality of life and prolong the healthspan of individuals with accelerated aging.

Detailed description

PRIMARY OBJECTIVES: I. Examine associations between social support, strain, and isolation and phenotypic aging over the 1-year recovery period. II. Examine associations between social support, strain, and isolation and biological aging over the 1-year recovery period. III. Test biological aging as a mediator linking social processes and phenotypic aging. EXPLORATORY OBJECTIVE: I. Test sex differences in Aims 1 and 2. OUTLINE: Adopting a prospective design, participants will complete comprehensive assessments of social processes at 100 days and 1 year after HCT that combine reports of social support, strain, and isolation with a naturalistic observation tool, the Electronically Activated Recorder (EAR), which captures ambient sound bites to assess social interactions in survivors' daily lives16. At each time point, participants will also provide reports of symptoms to characterize phenotypic aging, including cognitive, physical, and functional complaints, and blood samples to assess biological aging, including cellular senescence, DNA damage, SASP, and cellular stress using genome-wide RNA sequencing. Relevant clinical information that could influence biological aging will also be collected from patients' medical records to consider as covariates.

Interventions

PROCEDUREBiospecimen Collection

Undergo collection of blood sample

OTHERElectronic Health Record Review

Review of medical records

OTHERQuestionnaire Administration

Complete questionnaires

Sponsors

Medical College of Wisconsin
Lead SponsorOTHER
National Institute on Aging (NIA)
CollaboratorNIH

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Aged 18 years and older who are competent to give their informed consent. * Ability to read, speak, and understand English. * Received a hematopoietic cell transplant within the previous 100 days.

Exclusion criteria

* Less then Aged 18 years and older who are competent to give their informed consent. * Cannot read, speak, and understand English. * Has not received a hematopoietic cell transplant within the previous 100 days.

Design outcomes

Primary

MeasureTime frameDescription
The number of participants with gene expression of cellular senescence marker p16.Day 100 and 1 year post-transplantThis will be measured by mRNA/gene expression.

Countries

United States

Contacts

CONTACTMedical College of Wisconsin Cancer Center Clinical Trials Office
cccto@mcw.edu866-680-0505
PRINCIPAL_INVESTIGATORKelly Rentscher, PhD

Medical College of Wisconsin

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Aug 6, 2026